Dermato-neuro Syndrome after COVID-19 Vaccination in a Patient with Scleromyxoedema Previously Controlled with Bortezomib and Intravenous Immunoglobulins
DOI:
https://doi.org/10.2340/actadv.v102.4430Keywords:
Scleromyxedema, monoclonal gammopathy, intravenous immunoglobulins, bortezomib, dexamethasone, dermato‐neuro syndrome, COVID-19 Vaccine, plasmapheresisAbstract
Abstract is missing (Short communication)
Downloads
References
Rongioletti F, Merlo G, Cinotti E, Fausti V, Cozzani E, Cribier B, et al. Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol 2013; 69: 66-72.
https://doi.org/10.1016/j.jaad.2013.01.007 DOI: https://doi.org/10.1016/j.jaad.2013.01.007
Hoffmann JHO, Enk AH. Scleromyxedema. J Dtsch Dermatol Ges 2020; 18: 1449-1467.
https://doi.org/10.1111/ddg.14319 DOI: https://doi.org/10.1111/ddg.14319
Larios JM, Ciuro J, Sam Varghese T, Lyons SE. Successful treatment of dermato-neuro syndrome with plasmapheresis. BMJ Case Reports 2020; 13: 237170.
https://doi.org/10.1136/bcr-2020-237170 DOI: https://doi.org/10.1136/bcr-2020-237170
Knobler R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, et al. European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. J Eur Acad Dermatol Venereol 2017; 31: 1581-1594.
https://doi.org/10.1111/jdv.14466 DOI: https://doi.org/10.1111/jdv.14466
Haber R, Bachour J, El Gemayel M. Scleromyxedema treatment: a systematic review and update. Int J Dermatol 2020; 59: 1191-1201.
https://doi.org/10.1111/ijd.14888 DOI: https://doi.org/10.1111/ijd.14888
Ataergin S, Arpaci F, Demiriz M, Ozet A. Transient efficacy of double high-dose chemotherapy and autologous peripheral stem cell transplantation, immunoglobulin, thalidomide, and bortezomib in the treatment of scleromyxedema. Am J Clin Dermatol 2008; 9: 271-273.
https://doi.org/10.2165/00128071-200809040-00008 DOI: https://doi.org/10.2165/00128071-200809040-00008
Migkou M, Gkotzamanidou M, Terpos E, Dimopoulos MA, Kastritis E. Response to bortezomib of a patient with scleromyxedema refractory to other therapies. Leuk Res 2011; 35: 209-211.
https://doi.org/10.1016/j.leukres.2011.07.021 DOI: https://doi.org/10.1016/j.leukres.2011.07.021
Fett NM, Toporcer MB, Dalmau J, Shinohara MM Vogl DT. Scleromyxedema and dermato-neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib. Am J Hematol 2011; 86: 893-896.
https://doi.org/10.1002/ajh.22131 DOI: https://doi.org/10.1002/ajh.22131
Cañueto J, Labrador J, Román C, Santos-Briz A, Contreras T, Gutiérrez NC, García-Sanz R. The combination of bortezomib and dexamethasone is an efficient therapy for relapsed/refractory scleromyxedema: a rare disease with new clinical insights. Eur J Haematol 2012; 88: 450-454.
https://doi.org/10.1111/j.1600-0609.2012.01772.x DOI: https://doi.org/10.1111/j.1600-0609.2012.01772.x
Yeung CK, Loong F, Kwong YL. Scleromyxoedema due to a plasma cell neoplasm: rapid remission with bortezomib, thalidomide and dexamethasone. Br J Haematol 2012; 157: 411.
https://doi.org/10.1111/j.1365-2141.2012.09088.x DOI: https://doi.org/10.1111/j.1365-2141.2012.09088.x
Victor V, Margareat RM. Plasma cell myeloma masquerading as scleromyxedema. Indian Dermatol Online J 2019; 10: 50-53.
https://doi.org/10.4103/idoj.IDOJ_135_18 DOI: https://doi.org/10.4103/idoj.IDOJ_135_18
Win H, Gowin K. Treatment of scleromyxedema with lenalidomide, bortezomib and dexamethasone: a case report and review of the literature. Clin Case Rep 2020; 8: 3043-3049.
https://doi.org/10.1002/ccr3.3302 DOI: https://doi.org/10.1002/ccr3.3302
Kreidy M, Al-Hilli A, Yachoui R, Resnick J. Severe but reversible pulmonary hypertension in scleromyxedema and multiple myeloma: a case report. BMC Pulm Med 2020; 20: 8.
https://doi.org/10.1186/s12890-019-1020-6 DOI: https://doi.org/10.1186/s12890-019-1020-6
Fritz M, Tinker D, Wessel AW, Morris GM, Goldenberg L, Fesler M, et al. SARS-CoV-2: A potential trigger of dermato-neuro syndrome in a patient with scleromyxedema. JAAD Case Rep 2021; 18: 99-102.
https://doi.org/10.1016/j.jdcr.2021.10.027 DOI: https://doi.org/10.1016/j.jdcr.2021.10.027
Steelman AJ. Infection as an environmental trigger of multiple sclerosis disease exacerbation. Front Immunol 2015; 6: 520.
https://doi.org/10.3389/fimmu.2015.00520 DOI: https://doi.org/10.3389/fimmu.2015.00520
Published
How to Cite
License
Copyright (c) 2022 Rosella Gallo, Ilaria Trave, Emilia Cotzia, Roberto Russo, Aurora Parodi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
